Cargando…
Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants
Autores principales: | Skarzynski, Martin, Lindorfer, Margeret, Butera, Vicent, Vire, Berengere, Farooqui, Mohammed, Rader, Christoph, Taylor, Ronald, Wiestner, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649393/ http://dx.doi.org/10.1186/2051-1426-3-S2-P372 |
Ejemplares similares
-
P1303: POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS
por: Wiestner, A., et al.
Publicado: (2022) -
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate
por: Skarzynski, Martin, et al.
Publicado: (2013) -
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012) -
How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca(2+)
por: Taylor, Ronald P., et al.
Publicado: (2020) -
Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
por: Yang, Jiahui, et al.
Publicado: (2011)